Up-Front Payments of HCV Partnerships [This list does not purport to be complete. Items are listed in descending order of up-front amount.]<pre> Up-front Licensor Licensee Product Phase Cash($M) Date iHub reference VRTX JNJ Telaprevir 2 165* 6/06 <a href='read_msg.aspx?message_id=11830934'>#msg-11830934</a> ZGEN BMY IFN-Lambda 1 105 1/09 <a href='read_msg.aspx?message_id=34768182'>#msg-34768182</a> IDIX NVS NM283 2 100‡ 3/06 <a href='read_msg.aspx?message_id=10407463'>#msg-10407463</a> ITMN Roche ITMN-191 p.c. 60 10/06 <a href='read_msg.aspx?message_id=14356850'>#msg-14356850</a> HGSI NVS Albuferon 2 45 6/06 <a href='read_msg.aspx?message_id=11451787'>#msg-11451787</a> ANDS NVS ANA975 1 20 2/05 <a href='read_msg.aspx?message_id=6545305'>#msg-6545305</a> LG Ltd GILD LB84451 2 20 11/07 <a href='read_msg.aspx?message_id=24337514'>#msg-24337514</a> Genelabs GSK n/a p.c. 12.5 5/06 <a href='read_msg.aspx?message_id=11431616'>#msg-11431616</a> Medivir JNJ TMC435 p.c. 10 11/04 n/a Benitec PFE TT-033 p.c. n/a 1/08 <a href='read_msg.aspx?message_id=25817504'>#msg-25817504</a> *Ex-US rights only. ‡Includes $75M NVS paid for rights to NM283 and telbivudine in 2003. </pre>